Pharmigene, Inc. products

RT-PCR & SYBR Green based detection method: each sample requires only 2 PCR rxns for detecting of Human Leukocyte Antigen (HLA-B*1502) and Internal Control. Analysis is based on Ct values. A complete kit version has IVD approval from Department of Health, Taiwan.

RT-PCR & SYBR Green based detection method: each sample requires only 2 PCR rxns for detecting of HLA-B*5701 and Internal Control. Analysis is based on Ct values.

RT-PCR & SYBR Green based detection method: each sample requires only 2 PCR rxns for detecting of HLA-B*5801 and Internal Control. Analysis is based on Ct values. A complete kit version has IVD approval from Department of Health, Taiwan.

RT-PCR & SYBR Green based detection method: each sample requires only 2 PCR rxns for detecting of HLA-B*27 and Internal Control. Analysis is based on Ct values.

The HLA-A*3101 allele is associated with Carbamazepine (CBZ)-induced hypersensitivity reactions in patients of Northern European and Japan ancestry. HLA-A*3101 is located on chromosome 6 and belongs to the family of human leukocyte antigens. Detection of this allele can be used to identify patients who may be at greater risk of CBZ-induced hypersensitivity reactions.

RT-PCR & TaqMan® based detection method: each sample requires only 1 PCR rxns for surveying of relevant subtypes of VKORC1 (-1639). GG, GA, & AA subtypes controls are developed to establish the position of GG, GA, & AA subtypes for analysis. Analysis is based on the position of the test sample verses the positions of each subtypes. A complete kit version is CE marked and has IVD approval from Department of Health, Taiwan.

PGx test is a pharmacogenomics test that predicts how patients will respond to drug therapy based on their unique genetic profile. Individuals’s genetic differences can affect  different drug response (e.g. drug absorption, metabolism, or activity.)